Previous Article | Next Article ![]()
Journal of Bacteriology, August 2007, p. 5634-5641, Vol. 189, No. 15
0021-9193/07/$08.00+0 doi:10.1128/JB.00446-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Department of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, Massachusetts 02111
Received 26 March 2007/ Accepted 11 May 2007
|
|
|---|
|
|
|---|
-D-glutamyl-(L)-meso-diaminopimelyl-D-alanine (GlcNAc-anhMurNAc-L-Ala-D-Glu-Dap-D-Ala). It is imported via AmpG, a permease specific for GlcNAc-anhMurNAc and GlcNAc-anhMurNAc-peptides (anhydromuropeptides) (2). Once in the cytoplasm, anhydromuropeptides are further degraded into GlcNAc, anhMurNAc, murein tripeptide, and D-Ala by an anhMurNAc-L-Ala amidase, AmpD (13, 15); a ß-N-acetylglucosaminidase, NagZ (1, 37); and an L,D-carboxypeptidase, LdcA (31). Murein tripeptide is directly ligated to UDP-MurNAc by Mpl, a UDP-MurNAc:L-Ala-
-D-Glu-Dap ligase (21), thereby returning it to the pathway for synthesis of murein. GlcNAc and anhMurNAc are also made available for reuse by conversion to GlcNAc-6-phosphate, which can enter the glycolysis pathway or the pathway to generate UDP-GlcNAc, the main precursor of murein and lipopolysaccharide (28, 34-36). The GlcNAc derived from the murein sacculus is phosphorylated by NagK, a specific GlcNAc kinase, thus facilitating its utilization (34). The anhMurNAc is phosphorylated by an anhMurNAc kinase, AnmK, to generate MurNAc-6-phosphate (36), which is then converted to GlcNAc-6-phosphate by a MurNAc-6-phosphate etherase, MurQ (16, 35), thus allowing its utilization.
In cells lacking an enzyme involved in murein recycling, the substrate of the enzyme will accumulate in the cytoplasm unless another pathway exists to metabolize it or to export it to the medium. For example, anhMurNAc-tripeptide accumulates in cells lacking the AmpD anhMurNAc-L-Ala amidase (14), and GlcNAc-anhMurNAc accumulates in a mutant lacking the NagZ ß-N-acetylglucosaminidase (1). However, only a small amount of murein tripeptide accumulates in an mpl mutant (21), leading us to suspect that an enzyme is present that degrades murein tripeptide and to identify MpaA, which cleaves the
-D-Glu-Dap bond in the murein tripeptide (33). As expected, in an mpl mpaA double mutant, a very large amount of murein tripeptide accumulates (33). Surprisingly, in a mutant lacking NagK (GlcNAc kinase), GlcNAc does not accumulate, though in a nagA (GlcNAc-P deacetylase) mutant, both GlcNAc and GlcNAc phosphate accumulate, suggesting that another pathway to metabolize or to export free GlcNAc may be activated in a nagK mutant (34). In an anmK mutant, anhMurNAc accumulates in the medium instead of the cytoplasm, indicating that E. coli has an efflux pathway for anhMurNAc (36). As a final example of this phenomenon, in a murQ etherase mutant, the substrate, MurNAc phosphate, accumulates in the cytoplasm (35).
Surprisingly, in an ampD nagZ double mutant, in addition to the expected GlcNAc-anhMurNAc-tripeptide, a significant amount of the disaccharide, GlcNAc-anhMurNAc, accumulates (1), suggesting that another AmpD-like enzyme may exist in E. coli. This led us to identify and characterize the AmpD-like lipoprotein, AmiD, described here.
|
|
|---|
(argF-lac)] (14) was used as a parent strain. TP78B (nagB::Kan nagZ::Cm ampD mutant of TP71) (1) and TP72 (ampG::Kan mutant of TP71) (14) were constructed earlier. The ampD mutation in TP78B, which was derived from TP73 (14) and therefore was assumed to be
ampDE, was found to be a 1-bp deletion of the 509th nucleotide of the ampD open reading frame. This resulted in replacement of the C-terminal 14 amino acids of AmpD with an altered sequence of 29 amino acids. TP78BD (
amiD mutant of TP78B) and TP72D (
amiD and ampG::Kan mutant of TP71) were constructed as described below. The expression vector, pJG1, and a plasmid carrying the amiD (ybjR) open reading frame, pOCUS2-ybjR, were obtained from the E. coli Genome Project at the University of WisconsinMadison (http://www.genome.wisc.edu/index.htm). Plasmids pJG1AmiD, containing the amiD gene under the control of the T7 promoter, and pTrcAmiD, expressing AmiD from the Ptrc promoter, were constructed as described below. Cultures were grown in LB broth at 37°C with aeration unless otherwise noted. To label murein, cells were grown in M9 minimal medium (29) containing 0.1% Casamino Acids, 1 mM MgCl2, 1 µg of thiamine/ml, 200 µg of lysine/ml, and either 0.2% glucose or 0.6% glycerol as a carbon source, as indicated.
Construction of the amiD mutant.
amiD was deleted as described previously (4), using primers 5'-GCGTCAGCGGTACGGCGGTGAAAACGCGTCGATGAGAAGATGTAGGCTGGAGCTGCTTCG and 5'-CTGGCTACGCGACCACGGAAAACTGCCGCGCTAATCCTGCCCATGAATATCCTCCTTAGT (italicized sequences are homologous to the amiD-flanking sequence, and boldfaced sequences are homologous to the pKD3 vector sequence flanking the Cmr gene) and pKD3 as the template to synthesize the PCR product used for one-step inactivation. The Cmr gene replacement was confirmed by PCR with primers 5'-CTGATGGTTAGCGTCAG and 5'-AAACTGCCGCGCTAATC. To construct TP78BD, the amiD::Cm mutation was first transduced into TP73 (ampD mutant of TP71), and the Cmr cassette was removed by the FLP recombinase present in plasmid pCP20 as described elsewhere (4). This was followed by the transduction of nagZ::Cm (1) and nagB::Km (28) into the strain, to yield TP78BD. TP72D was constructed by the transduction of amiD::Cm into TP72. TP71amiAC (amiA::Cm amiC::Km mutant of TP71) was constructed by transduction of amiA::Cm and amiC::Km mutations (11). TP71amiACD (
amiD amiA::Cm amiC::Km mutant of TP71) was constructed by transduction of amiD::Cm and removal of the Cmr cassette by the FLP recombinase, followed by transduction of the amiA::Cm and amiC::Km mutations (11). All transductions were performed with T4gt7 phage (22).
Measurement of murein breakdown products labeled with [6-3H]GlcN or [3H]Dap. Cells were labeled for 4 to 5 generations in the glycerol Casamino Acid minimal medium containing 1 µCi of [6-3H]glucosamine ([6-3H]GlcN) (21.6 Ci/mol; Perkin-Elmer, Waltham, MA)/ml as described previously (28) or in the glucose Casamino Acid minimal medium containing 1 µCi of [3H]Dap (20 Ci/mmol; Moravek Biochemicals, Inc., Brea, CA)/ml as described previously (14). To label cells exclusively in their amino sugars with [6-3H]GlcN, a nagB mutation was introduced into the strain. When cells were labeled with [3H]Dap, lysA mutants were used to prevent the conversion of Dap to lysine. The amounts of radioactivity in the murein degradation products present in the cytoplasm of labeled cells were determined by analysis of hot-water extracts of cells by high-performance liquid chromatography (HPLC) as described below. When required, the spent medium was analyzed by HPLC.
HPLC analysis. The amounts of GlcNAc-anhMurNAc tripeptide and GlcNAc-anhMurNAc in hot-water extracts from TP78B and TP78BD were measured by HPLC as described previously (1, 33). All other samples were separated by a Waters Symmetry C18 reverse-phase column (4.6 by 150 mm; particle size, 5 µm; Waters Co., Milford, MA) employing a Waters 1525 binary HPLC pump, a Waters 2487 dual-wavelength absorbance detector, and Waters Breeze software (Waters Co., Milford, MA). Compounds were eluted at a flow rate of 0.5 ml/min with isocratic elution with solvent A for 10 min, followed by a linear gradient of 0 to 20% solvent B over a period of 70 min. Two solvent systems were used as indicated: either 0.1% formic acid (solvent A) and 0.1% formic acid in acetonitrile (solvent B) or 0.05% trifluoroacetic acid (solvent A) and 0.035% trifluoroacetic acid in acetonitrile (solvent B).
Preparation of substrates. The radioactive intermediates in the murein recycling pathway were purified by HPLC from hot-water extracts of mutants as described previously (36). [3H]GlcNAc-[3H]anhMurNAc was purified from nagZ mutant cells labeled with [6-3H]GlcN. The [3H]GlcNAc-anhMurNAc-tripeptide was from a nagZ ampD double mutant labeled with either [6-3H]GlcN or [3H]Dap. The [3H]Dap-labeled anhMurNAc-tripeptide was prepared from the [3H]Dap-labeled GlcNAc-anhMurNAc-tripeptide by treatment with ExoII, a ß-N-acetylglucosaminidase from Vibrio furnissii purified as described elsewhere (3), followed by purification using HPLC (36).
anhMurNAc-L-Ala amidase assay. The radioactive GlcNAc-anhMurNAc-tripeptide was incubated with cellular fractions or purified AmiD at 37°C. Following heat inactivation, the substrate and the radioactive product were separated by HPLC. When the enzyme solution contained 1 mM EDTA, 2 mM ZnCl2 was added to the reaction mixture.
Cellular fractionation of the periplasmic, membrane, and cytoplasmic proteins by using osmolysis. During fractionation steps, phenylmethylsulfonyl fluoride (PMSF) and EDTA were added to inhibit proteases, because otherwise AmiD might be detached from the membrane by cellular proteases. This actually occurred in the case of MltB, a lipoprotein that was originally reported to be a soluble lytic transglycosylase, Slt35 (5, 6). TP78B cells from 40 ml of culture in log phase were chilled, harvested, and resuspended in 4 ml of TE buffer (10 mM Tris-HCl [pH 8.0], 1 mM EDTA) containing 20% sucrose, 10 µg/ml of lysozyme (freshly made, 10 mg/ml dissolved in water), and 1 mM PMSF (freshly made, 100 mM dissolved in dimethyl sulfoxide). The suspension was placed on ice for 30 min and centrifuged (at 3,000 x g for 5 min at 4°C). The supernatant contained the periplasmic fraction. The pellet was suspended in 4 ml of TE buffer and centrifuged (at 3,000 x g for 5 min at 4°C). Two milliliters of the supernatant was ultracentrifuged (at 200,000 x g for 60 min at 4°C) using a 100.3 rotor (Beckman Coulter, Fullerton, CA), and the pellet (membrane fraction) was resuspended in 0.2 ml of TE buffer. The supernatant was the cytoplasmic fraction.
Membrane fractionation by sucrose gradient centrifugation. Inner and outer membranes were separated as described previously (23, 27) with the following modification: TP78B/pTrcAmiD cells were grown at 37°C in 1 liter of LB broth containing 100 µg of ampicillin/ml and 0.2% glucose. When the culture reached late log phase, 50 µM isopropyl-ß-D-thiogalactoside (IPTG) was added to half of the culture (500 ml) to induce AmiD. After an hour, cells in the induced and uninduced cultures were chilled, harvested, washed, resuspended in 5 ml of TE buffer containing 20% sucrose, and frozen. Cells thawed in the presence of 200 µg of PMSF/ml were broken by a French press at 15,000 lb/in2 twice. Unbroken cells were removed by low-speed centrifugation. The suspension was centrifuged (at 200,000 x g for 2 h at 4°C), and the pellet (membrane fraction) was resuspended in 0.5 ml of TE buffer containing 20% sucrose. The membrane fraction was loaded on top of a 12-ml sucrose density gradient (30 to 60% [wt/wt] sucrose in TE buffer) formed by Gradient Master (Biocomp Instruments Inc., Brunswick, Canada), and then the tube was centrifuged at 200,000 x g for 42 h at 4°C in an SW41 rotor (Beckman Coulter, Fullerton, CA). Fractions of 1 ml were collected with a piston gradient fractionator (Biocomp Instruments Inc., Brunswick, Canada). Aliquots (20 µl) of the fractions were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) with staining with Coomassie brilliant blue (CBB) (29), and 0.1-µl aliquots were used for the amidase assay.
Construction of plasmids overexpressing AmiD. A pJG1AmiD plasmid was constructed by ligation of a SapI-digested 828-bp fragment of pOCUS2-ybjR into the SapI site of the pJG1 vector. The 872-bp HindIII-XbaI fragment of pJG1AmiD was cloned into the HindIII-XbaI-digested vector pTrc99a, generating pTrcAmiD. To express AmiD in the cytoplasm, a plasmid with AmiD containing hexahistidine instead of the signal sequence was constructed. The amiD DNA fragment amplified from pTrcAmiD by PCR using 5'-GAGGAATTCGCAGGCGAAAAAGGCATTG and 5'-CGCAAGCTTTAATCCTGCCC was digested with EcoRI and HindIII and ligated into the EcoRI and HindIII sites of the pET28a vector (Promega, Madison, WI), generating plasmid pET28a-AmiD. The DNA approaches were based on methods described previously (29), and the XL1-Blue strain (Stratagene, La Jolla, CA) was used as a host for DNA cloning.
Overexpression and purification of AmiD. All purification steps were performed at 4°C or on ice unless otherwise noted. BL21(DE3) cells (Stratagene, La Jolla, CA) carrying plasmid pJG1AmiD were grown in 2 liters of LB broth supplemented with 100 µg ampicillin/ml and 0.2% glucose, and at late-log phase 1 mM IPTG was added to the culture. After 3 h of induction, cells were chilled, harvested, washed, resuspended in 20 ml of 50 mM Tris-HCl (pH 8.0) containing 0.3 M NaCl, and broken by sonication. Following low-speed centrifugation, the supernatant was centrifuged at 100,000 x g for 60 min. The pellet was washed with 50 mM Tris-HCl (pH 8.0) containing 1 M NaCl and ultracentrifuged twice. About 80% of the protein in the pellet was AmiD, as judged by SDS-PAGE and CBB staining. The pellet was resuspended by stirring overnight at 4°C in 10 ml of buffer containing 50 mM Tris-HCl (pH 8.0), 1 M NaCl, 2% Triton X-100, and 1 mM PMSF; then it was ultracentrifuged. In this step, while about one-half of the AmiD was solubilized together with other membrane proteins, the pellet fraction contained the other half of AmiD, which now represented 90% of the protein in the fraction. The pellet was resuspended again in the same buffer overnight and ultracentrifuged. In a final purification step, the sample was dialyzed against 20 mM Tris-HCl (pH 8.0) containing 1% Triton X-100 and was then loaded onto a MonoQ HR 5/5 column (Amersham Pharmacia, Uppsala, Sweden), followed by the elution of AmiD with a linear gradient of 0 to 0.5 M NaCl. AmiD was eluted at around 100 mM NaCl in 20 mM Tris-HCl (pH 8.0) containing 1% Triton X-100. Purified AmiD was stable at 80°C for at least 2 years.
His-tagged AmiD was overexpressed in BL21(DE3)/pET28a-AmiD cells with 1 mM IPTG for 3 h and purified from the cell extract with a HiTrap chelating HP column (1 ml) (Amersham Pharmacia, Uppsala, Sweden) by following the manufacturer's instructions.
Digestion of murein by AmiD. E. coli sacculi were purified from log-phase cells by the method described by Glauner (8). Two hundred fifty micrograms of sacculi (murein) was incubated with 2.5 µg of purified AmiD in 50 µl of 10 mM HEPES-NaOH (pH 7.0) at 37°C overnight. Following centrifugation (at 14,000 x g for 10 min at room temperature), the soluble components were separated by HPLC with the trifluoroacetic acid solvent system. The products were detected by their UV absorbances at 206 nm. The three main fractions were recovered, lyophilized, and identified by mass spectrometry with a Voyager DE Pro matrix-assisted laser desorption ionizationtime-of-flight (MALDI-TOF) mass spectrometer (Applied Biosystems, Foster City, CA) at the Tufts Core Facility.
|
|
|---|
![]() View larger version (16K): [in a new window] |
FIG. 1. Alignment of the amino acid sequences of the AmpD amidase and YbjR (AmiD) from Escherichia coli by the T-Coffee program (25). Identical amino acids and conserved substitutions are indicated by asterisks and colons, respectively. Dashes indicate a gap in the sequence. Amino acid numbers for both proteins are given on the right. The residues of the zinc-binding triad His34-His154-Asp164 of AmpD are shaded, and the lipobox sequence (L14AGC17) of YbjR is underlined.
|
![]() View larger version (36K): [in a new window] |
FIG. 2. Effect of AmiD on the GlcNAc-anhMurNAc content of ampD nagZ cells. Shaded bars, the amiD+ strain TP78B (nagB nagZ ampD); solid bars, the amiD deletion mutant TP78BD (nagB nagZ ampD amiD). Cells were labeled with [6-3H]GlcN in 4 ml of M9 glycerol minimal medium, and hot-water extracts were analyzed by HPLC. The amounts of radioactivity in the fractions corresponding to GlcNAc-anhMurNAc, UDP-MurNAc-pentapeptide, and GlcNAc-anhMurNAc-tripepide were measured and adjusted to equal cell populations. Values are averages from two separate experiments.
|
|
View this table: [in a new window] |
TABLE 1. anhMurNAc-L-Ala amidase activity in various cell fractions
|
ampD cells in which AmiD was the only active anhMurNAc-L-Ala amidase. As shown in Table 1, the amidase activity was present only in the membrane fraction. It is known that the amino acid next to the cysteine that carries diacylglycerol determines whether a lipoprotein resides in the inner or outer membrane (30, 32). Since the amino acid following the lone cysteine in AmiD is alanine, AmiD was expected to be transferred to the outer membrane. To establish this, the inner and outer membranes of ampD cells overexpressing AmiD were separated by sucrose gradient centrifugation. The majority of the overproduced protein was present in the outer membrane fraction (Fig. 3), and most AmiD amidase activity was present in the outer membrane, indicating that AmiD is indeed located in the outer membrane.
![]() View larger version (85K): [in a new window] |
FIG. 3. Subcellular location of AmiD. Membranes of TP71/pTrcAmiD cells before (lanes 1, 3, and 5) and after (lanes 2, 4, and 6) induction of AmiD for 1 h following the addition of 50 µM IPTG were separated by sucrose gradient centrifugation into inner membrane (lanes 1 and 2), intermediate membrane (lanes 3 and 4), and outer membrane (lanes 5 and 6) fractions. The samples were fractionated by SDS-PAGE and stained with CBB. Arrow indicates AmiD protein. Each value below the gel is the percentage of [3H]GlcN-labeled GlcNAc-anhMurNAc-tripeptide (1,000 cpm) cleaved by 1/200 of the fraction loaded on the SDS-PAGE gel and was determined by incubation with the substrate at 37°C for 30 min, followed by heat inactivation and thin-layer chromatographic analysis.
|
![]() View larger version (13K): [in a new window] |
FIG. 4. Overexpression of AmiD inhibits growth. TP71 carrying pTrcAmiD was grown at 37°C in LB broth containing 100 µg ampicillin/ml and 0.2% glucose. IPTG (100 µM) was added at a turbidity of 52 Klett units (filled triangles) or 100 Klett units (filled circles), as indicated by the arrows. Open squares, control culture.
|
Characterization of AmiD activity. Since AmpD is highly specific for the anhMurNAc-L-Ala bond (15), one would predict that AmiD might be equally specific because of the homology between them. To test this, AmiD was overproduced and purified from the membrane fraction. Two hundred fifty nanograms of purified AmiD completely cleaved 13.5 kcpm of [3H]GlcNAc-[3H]anhMurNAc-L-Ala-D-Glu-[3H]Dap in 30 min at 37°C to release the tripeptide L-Ala-D-Glu-[3H]Dap and [3H]GlcNAc-[3H]anhMurNAc (Fig. 5).
![]() View larger version (17K): [in a new window] |
FIG. 5. HPLC analysis of GlcNAc-anhMurNAc-L-Ala-D-Glu-Dap before (dashed line) and after (solid line) digestion with AmiD. A mixture of 11 kcpm of [3H]GlcNAc-[3H]anhMurNAc-tripeptide and 2.5 kcpm of GlcNAc-anhMurNAc-L-Ala-D-Glu-[3H]Dap was incubated with 0.25 µg of purified AmiD at 37°C for 30 min and separated by HPLC with the formic acid solvent system. Fraction A, L-Ala-D-Glu-Dap; fraction B, GlcNAc-anhMurNAc; fraction C, GlcNAc-anhMurNAc-L-Ala-D-Glu-Dap.
|
|
View this table: [in a new window] |
TABLE 2. AmiD prefers a substrate containing GlcNAc-anhMurNAca
|
![]() View larger version (19K): [in a new window] |
FIG. 6. Cleavage of muropeptides by AmiD. Purified sacculi were first digested with 10 U of mutanolysin (Sigma, St. Louis, MO) at 37°C overnight in 10 mM morpholineethanesulfonic acid-NaOH (pH 6.0), followed by incubation with (black line) or without (gray line) 5 µg of AmiD in 50 mM HEPES-NaOH (pH 7.0) overnight. The samples were reduced with sodium borohydride and separated by HPLC with the trifluoroacetic acid solvent system. Based on the elution time, peak A corresponds to cross-linked tetra-tetrapeptide; peak B, GlcNAc-MurNAc tetrapeptide; peak C, cross-linked GlcNAc-MurNAc tetrapeptide-tetrapeptide-MurNAc-GlcNAc.
|
![]() View larger version (29K): [in a new window] |
FIG. 7. Release of peptides from murein by AmiD. A 0.2-mg portion of purified murein digested by purified AmiD was separated by HPLC with the trifluoroacetic acid solvent system as described in Materials and Methods. Compounds in the three main peaks (A, B, and C) were collected, lyophilized, and analyzed by MALDI-TOF mass spectrometry. Fraction A, L-Ala-D-Glu-Dap (m/z 391) tripeptide; fraction B, L-Ala-D-Glu-Dap-D-Ala (m/z 462) tetrapeptide; fraction C, tetra-tetrapeptide (m/z 905).
|
Does AmiD play a significant role in the metabolism of the murein sacculus or the anhydromuropeptides released during growth? We have shown that AmiD is present in the outer membrane and cleaves the bond between N-acetylmuramic acid and L-Ala in intact sacculi, in muropeptides, and in anhydromuropeptides. The question arises whether AmiD has a demonstrable effect in growing cells. In order to address this question, we compared the effect of an amiD deletion in our standard strain, TP71, and in TP72, a strain lacking the AmpG permease. Cultures were grown in the presence of [3H]Dap for about 5 generations. Comparison of the spent medium of the ampG strain with that of an ampG amiD strain by HPLC revealed that GlcNAc-anhMurNAc-tripeptide and GlcNAc-anhMurNAc-tetrapeptide accumulated in the medium when AmiD was absent from the ampG strain (Fig. 8). In contrast, when AmiD was present, the anhydromuropeptides were cleaved by AmiD amidase and free tetrapeptide accumulated in the medium. We were unable to measure the amount of free tripeptide in the spent medium, because the HPLC method did not resolve the relatively small amount of tripeptide from the huge amount of radioactive Dap present. The effect of AmiD in the ampG-positive cells was small: the amount of free tetrapeptide in the medium was reduced only twofold by the amiD mutation (Fig. 8). This indicates that the anhydromuropeptides are swept into the cytoplasm rapidly through the AmpG permease.
![]() View larger version (64K): [in a new window] |
FIG. 8. Amounts of Dap-containing compounds in the spent medium from cultures growing for about 5 generations in 2 ml of M9 minimal medium containing 1 µCi of [3H]Dap/ml. The medium was lyophilized and analyzed by HPLC to measure the amount of each compound. wt, wild type; anhD, GlcNAc-anhMurNAc.
|
|
|
|---|
The small amount of GlcNAc-anhMurNAc generated by cells lacking AmiD, AmpD, and NagZ had led us to speculate that E. coli has another anhMurNAc-L-Ala amidase. In fact, E. coli has three periplasmic murein amidases, AmiA, AmiB, and AmiC, which cleave the MurNAc-L-Ala bonds of peptidoglycan (11). AmiA, AmiB, and AmiC are similar to each other but not to either AmiD or AmpD. Since the cell extract from the amiD ampD double mutant completely lacked the activity to cleave the anhMurNAc-L-Ala bond (Table 1), AmiD and AmpD were the only enzymes present in E. coli that cleave the anhMurNAc-L-Ala bond. Hence, AmiA, AmiB, and AmiC must not cleave the anhMurNAc-L-Ala bond under the conditions tested. The expression levels of AmiA, AmiB, and AmiC amidases in the ampD amiD mutant should be similar to those of its parent cells, because the double mutant did not produce any chained cells, which amiA, amiB, or amiC mutants produce (11). Probably the 1,6-anhydro bond in the MurNAc moiety interferes with the activities of these amidases. Since major peptidoglycan glycosyl hydrolases of E. coli are lytic transglycosylases that form GlcNAc-anhMurNAc-peptides (12), the GlcNAc-anhMurNAc accumulating in an ampD amiD nagZ mutant must be derived from the cleavage of MurNAc-L-Ala bonds of intact murein by the periplasmic amidases, followed by the action of lytic transglycosylases, such as Slt70 (12).
Like AmpD, purified AmiD cleaved the anhMurNAc-L-Ala bond and required Zn2+ for its activity. Unlike AmpD, AmiD preferred a substrate containing GlcNAc-anhMurNAc to a substrate containing only anhMurNAc. Interestingly, AmiD also cleaved MurNAc-L-Ala bonds in murein. The crystal structure of AmiD from E. coli is available at the RCSB Protein Data Bank (http://www.rcsb.org/pdb/), though it is not published. The AmiD structure (PDB IDs, 2BGX and 2BH7) contains a zinc ion bound to a triad (His50-His166-Asp176) of AmiD, two residues of which were aligned with the zinc triad of AmpD shown in Fig. 1. The broad substrate specificity of AmiD indicates that the active site of AmiD must be much more accessible than that of AmpD. However, both zinc ions of the active sites of the crystal structure of AmiD and the nuclear magnetic resonance structure of AmpD (19) appear to be surface exposed. Hence, more crystallographic and biochemical studies are required to explain the difference in the substrate specificities of AmpD and AmiD. The amino acid alignment of AmpD and AmiD (Fig. 1) also shows that AmiD has an extra C-terminal tail consisting of about 100 amino acids, which weakly resembles a peptidoglycan-binding sequence. In the crystal structure of AmiD, it appears to form a domain distant from the zinc ion of the active center.
We have also shown that AmiD exists in the outer membrane. Considering the facts that the signal sequence of AmiD has the features of an outer membrane lipoprotein and that AmiD lacking its signal sequence forms a soluble, active enzyme in the cytoplasm, it was not unexpected that AmiD proved to be tethered to the outer membrane. Unpublished experiments mentioned in reference 17 have also shown that YbjR (AmiD) is a lipoprotein.
AmiD was shown to be active in growing cells by the demonstration that nagZ cells lacking both AmpD and AmiD contained more GlcNAc-anhMurNAc-tripeptide than nagZ cells lacking only AmpD (Fig. 2). Overexpression of AmiD inhibited cell growth, followed by a slow loss of turbidity which may be the result of AmiD hydrolytic activity on peptidoglycan. However, another reason could be that the amiD gene has tandem rare arginine codons, AGA_AGA, as its second and third codons. When overexpressed, an mRNA with a pair of the rare codons near the initiation codon is known to interfere with protein synthesis and hence to inhibit cell growth (26, 40).
Though AmiD has the same activity on murein as the periplasmic amidases involved in cell separation, AmiD did not participate in cell separation. This may be because AmiD is attached to the outer membrane, which may prevent the movement of AmiD to the septum.
It is known that during growth E. coli releases the murein peptides L-Ala-D-Glu-Dap-D-Ala, L-Ala-D-Glu-Dap, and Dap-D-Ala to the medium (10). We also observed the release of the tetrapeptide to the medium (Fig. 8). When AmpG permease is absent, the anhydromuropeptides derived from murein accumulate in the periplasm rather than being returned to the cytoplasm for recycling. Under these circumstances, AmiD is able to cleave most of the anhydromuropeptides in the periplasm. Though one might predict that the accumulation of the murein breakdown products in the periplasm would induce AmiD expression, the AmiD activity in the ampG mutant was the same as that in its parent strain (data not shown). Surprisingly, in ampG cells lacking AmiD, huge amounts of the uncleaved anhydromuropeptides, with molecular weights of 850 (GlcNAc-anhMurNAc-tripeptide) and 921 (GlcNAc-anhMurNAc-tetrapeptide), were released into the medium. This suggests that even compounds that exceed the "exclusion limit" of 600 Da (24) can cross the outer membrane if the concentration gradient is large. However, the release of GlcNAc-anhMurNAc-peptides from Bordetella pertussis (9), Neisseria gonorrhoeae (20), and Vibrio fischeri (18) in amounts sufficient to destroy ciliated epithelial cells illustrates that significant release occurs even in bacteria possessing orthologs of AmpG. Peptidoglycan degradation products also induce innate immune responses (3a). The peptidoglycan recycling pathway starting with the import of the breakdown products via AmpG permease into the cytoplasm could be a primary bacterial strategy to avoid innate immune responses in these environments. AmiD may function as a secondary bacterial strategy to avoid innate immune responses in these environments by degrading the bioactive compounds in the periplasm.
This work was supported by Public Health Service grant GM51610 from the National Institute of General Medical Sciences.
Published ahead of print on 25 May 2007. ![]()
|
|
|---|
-D-glutamyl-meso-diaminopimelate ligase in Escherichia coli and its role in recycling of cell wall peptidoglycan. J. Bacteriol. 178:5347-5352.
-D-glutamyl-meso-diaminopimelate bond in murein peptides. J. Bacteriol. 185:679-682.This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»